John M. Evans sold $1.1M of BEAM
CEO at Beam Therapeutics Inc.. 50,000 shares at an average of $22.57, traded Mar 30, 2026, filed Apr 1, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 4.9% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +26.8%, 3m +38.2%, 6m +0.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-138348, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Apr 1, 2026 |
| Mar 30, 2026 | SOpen-market sale Common Stock10b5-1 | -25,000 | $22.37 | $559k | 986,667 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Common Stock10b5-1 | +25,000 | $0.67 | $17k | 1,011,667 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -25,000 | $22.76 | $569k | 986,667 | Apr 1, 2026 |
| Mar 31, 2026 | AGrant or award Common Stock10b5-1 | +90,000 | $0.00 | $0 | 1,076,667 | Apr 1, 2026 |
| Mar 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 43,672 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 18,672 | Apr 1, 2026 |
Related signals
Other insiders at Beam Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $4,565 187 shares | -0% | |
| 17Weak | Beam Therapeutics Inc. | Amy Simon Chief Medical Officer | $429k 16,667 shares | -16% | |
| 10Weak | Beam Therapeutics Inc. | Amy Simon Chief Medical Officer | $13k 373 shares | -0% | |
| 30Weak | Beam Therapeutics Inc. | John M. Evans CEO | $1.7M 50,000 shares | -5% | |
| 57Moderate | Beam Therapeutics Inc. | Fmr LLC owner, other | $10M 284,860 shares | -25% | |
| 29Weak | Beam Therapeutics Inc. | Giuseppe Ciaramella President | $290k 11,810 shares | -5% | |
| 21Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $146k 5,956 shares | -5% | |
| 26Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $80k 3,242 shares | -6% | |
| 21Weak | Beam Therapeutics Inc. | Amy Simon Chief Medical Officer | $165k 6,700 shares | -6% | |
| 41Moderate | Beam Therapeutics Inc. | John M. Evans CEO | $739k 30,078 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.